

ASX Release

Anatara Investor Presentation

BRISBANE & MELBOURNE, 19th February 2019: Anatara Lifesciences (ASX:ANR) is pleased to release a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will be presenting at the Proactive Investors Australia *CEO Sessions* and the Wholesale Investor's *Emergence 2019* conferences this month.

Details for Mr Lydeamore's presentations are as follows:

- Proactive Investors Australia - CEO Sessions
 - Tuesday 19th February 2019 - arrive from 11:15am
 - CQ Functions, 113 Queen Street, Melbourne
- Wholesale Investor's - Emergence 2019
 - Thursday 28th February 2019 – 9am until 6pm
 - InterContinental Sydney, L2 117 Macquarie Street, Sydney

A copy of the presentation is attached.

The Anatara team plans a further market update and extensive investor roadshow in March.

For more information please contact:

Investor inquiries	Media inquiries
Mr Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Jane Lowe Managing Director, IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.





Bringing Science to Supplements

February 2019



ANATARA
LIFESCIENCES

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.



Key Investor Message

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health



Key Financial Details


ASX Code ANR	Market Capitalisation¹ \$24.7 million	Share Price¹ \$0.50
Current Cash² \$6.0 million	Ordinary Shares 49,413,236	Options 2,346,000

- ~\$1.25m **R&D tax refund** received for 2017-18 activities
- **Sufficiently funded** to execute on the development and partnering of our first human product



¹ As at 11 February 2019

² Appendix 4C - 31 December 2018 (\$1.5m cash, \$4.5m deposits with terms greater than 90days)



Company Highlights


- Detach (exclusive global license to **Zoetis Inc.**)
 - **APVMA approved** for use in piglets
- Key appointments with significant **human health experience**
 - Sue MacLeman, Dr Jane Ryan, Dr David Brookes, Steve Lydeamore
- First human product candidate
 - **Gastrointestinal ReProgramming (GaRP) dietary supplement** is aimed at restoring and maintaining **gut health**
 - Significant **unmet market need** for **IBS** and **IBD** patients
 - **World-leading scientists and clinicians** form our Product Development Advisory Board
 - **Successful *in vitro* proof of concept studies**
 - **18 – 24 months to partnering milestone**



Animal Health

- Detach is a natural, safe, non-antibiotic product that **aids in the control of diarrhoea** (known as scour) in livestock
- In May 2018, Anantara signed an **exclusive licensing agreement with Zoetis Inc.**, the leading global animal health company, for the **worldwide development, manufacturing, distribution, and marketing of Detach** for livestock animals and horses
- Upfront payment of US\$2.5m, aggregate milestone payments of up to US\$6.3m and royalty of 3-4%³
- In October 2018, the Australian Pesticides and Veterinary Medicines Authority (**APVMA**) **registered Detach for use in piglets in Australia**





From animals to humans

Market Opportunity

Irritable Bowel Syndrome (IBS)

Affects around **11%** of the global population⁴
~50% of patients⁵ turn to dietary supplements and complementary medicines

Inflammatory Bowel Disease (IBD)

>5 million sufferers globally⁶
30-50% of IBD patients⁷ turn to complementary and alternative medicines

Low grade **inflammation**



Chronic **inflammation**



Shared disease characteristics:

Altered microbiome
Impaired intestinal barrier function
Mucosal damage

Patient Story


- You will now hear from patient, Adam, who is living with IBS and the impact the condition has had on his life. Adam highlights his most difficult symptoms to manage and his own experiences with the effectiveness of current therapies and management practices.



Gastrointestinal ReProgramming (GaRP) Dietary Supplement

How does it work?

GaRP is a microbiome-targeted dietary supplement aimed at:



GaRP could be used as a sole therapy and as an adjunct therapy in combination with current IBD and IBS prescription medications.


Scientifically Proven

Successful Proof of Concept Studies

- Potential breakthrough dietary product
- Anatará's proprietary GaRP formulation was⁹ efficacious and:
 - Reduced production of pro-inflammatory proteins by gut and inflammatory cells by >85%;
 - Reduced the attachment and invasion of IBD and IBS pro-inflammatory bacteria into healthy gut cells by >95%;
 - Protected and maintained gut integrity.



Dual targeted product combining bromelain and other GRAS components



Ileum

Colon

Ileum targeted components

- prevent attachment of pro-inflammatory bacteria
- restore gut microbiota
- reduce inflammation

Colon targeted components

- restore gut microbiota
- reduce inflammation
- mucosa regeneration
- restore gut integrity
- reduce diarrhoea

Advantages of Dietary Supplements*

The advantages of a dietary supplement regulatory strategy are:

Fewer or lower regulatory requirements than pharmaceuticals¹⁰

->Lower development cost


->Lower development risk

->Faster time to market

Rapid market penetration¹¹

Public and health care professionals understand the term 'dietary supplement'

Marketing can be aimed at both the public and the professional



* Dietary Supplement are foods intended to supplement the normal diet which are concentrated sources of one or more nutrients, like vitamins, proteins, mineral complexes, herb or other botanical, amino acid or enzymes.

Clear Path to Commercialisation

	2017 H1	2017 H2	2018 H1	2018 H2	2019 H1	2019 H2	2020 H1	2020 H2
Confirmed GRAS status for components with FDA	✓							
Established collaboration with University of Liverpool (UK)		✓						
Completed product development plan		✓						
Patent Application filed				✓				
Commercial feasibility			✓					
Manufacturing – sourced suppliers		✓						
Proof of concept				✓				
Animal study (IBD)						F*		
Human observational study (IBS)						S*		
Partnering discussions								F*

* Finish; Start



Anatara Lifesciences Ltd (ASX:ANR) Summary

- Innovative, evidence-based products, backed by scientific and clinical studies for gastrointestinal health
- GaRP dietary supplement seeks to target IBS and IBD patients
 - Patentable multi-component, dual-targeted formulation
 - Delivers the components where they can be most effective
- Board and Management have significant deal experience
- 18 – 24 months to partnering milestone



Steven Lydeamore, CEO
slydeamore@anataralifesciences.com

www.anataralifesciences.com



@AnataraANR

